Zhong Ji Longevity Science Group Announces Strategic AI Vision Health Joint Venture in China

Date: 13 April 2026
Company: Zhong Ji Longevity Science Group Limited (Stock Code: 767)

Key Highlights of the Announcement

• Formation of a Joint Venture: Zhong Ji Longevity Science Group Limited (“the Company”) has entered into a joint venture agreement with Guangdong Liangjingjing Technology Company Limited (“Liangjingjing”) through its wholly-owned subsidiary, Shenzhen Zhong Ji Health Science Company Limited (“Zhong Ji Health”). The joint venture will be established in the People’s Republic of China.
• Ownership Structure: Zhong Ji Health will hold a majority 51% stake in the joint venture, while Liangjingjing will hold the remaining 49%.
• Capital Commitment: The initial registered capital of the joint venture will be RMB 1,000,000, contributed by the parties in proportion to their shareholdings. This capital will mainly serve as working capital for the joint venture.
• Business Scope: The joint venture will focus on the provision of AI-powered vision health and longevity products and services globally, aiming to build the world’s first AI+ vision health ecosystem platform.

Strategic Details and Rationale

• Innovative Technology Collaboration: Liangjingjing is a high-tech, innovative company specializing in AI+ eye health, with strong scientific research capabilities and significant professional influence in the field. It is renowned for its expertise in AI-powered eye health large language models, AI-driven optic nerve and visual technology, and smart vision training equipment. Liangjingjing leverages cutting-edge technologies from the US, Germany, and Japan to provide precise solutions for various vision problems.
• Market Opportunity: The Company’s Board believes that the health longevity science market is poised for substantial growth, driven by increasing consumer focus on health management, longevity, and well-being. The Company sees significant opportunity in providing products that enhance immune function, delay aging, and maintain vitality.
• Product Pipeline and Ecosystem: The joint venture aims to launch flagship products such as the world’s only AI-powered vision-correcting glasses, IPS exosome eye drops, and a lutein product range. The goal is to create a comprehensive, closed-loop AI eye health ecosystem and establish leadership in the global technology-driven eye care market.
• Financial Impact: The Company will finance its capital commitment from internal resources. The joint venture is expected to create new revenue streams and contribute to long-term sustainable growth.
• Governance and Fairness: The terms of the joint venture agreement were reached after arm’s length negotiations and are considered fair, reasonable, and in the best interest of the Company and its shareholders.
• Independence Confirmation: Liangjingjing and its ultimate beneficial owners are independent of Zhong Ji Longevity Science Group and its connected persons, ensuring regulatory compliance and reducing potential conflicts of interest.

Implications for Shareholders and Investors

• Potential Price-Sensitive Information: The formation of this joint venture positions Zhong Ji Longevity Science Group at the forefront of tech-driven health longevity markets, with a focus on AI and global expansion. This strategic move could have a significant positive impact on the Company’s revenue streams and market positioning, potentially affecting the Company’s share value.
• Caution Advised: The Company advises shareholders and potential investors to exercise caution when dealing in the Company’s shares, as the joint venture represents a major strategic initiative with growth potential, but also inherent business and execution risks.

Board and Management

• Executive Leadership: The announcement was signed by Mr. Yan Li, Chairman, Chief Executive Officer, and Executive Director. The Board includes a mix of executive, non-executive, and independent non-executive directors, ensuring a balance of expertise and oversight.

Conclusion

The strategic partnership with Liangjingjing and the formation of an AI-powered eye health joint venture is a pivotal development for Zhong Ji Longevity Science Group. This move aligns with the Company’s commitment to innovation in health longevity and has the potential to unlock new markets and revenue opportunities, marking a significant milestone in its growth trajectory.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult professional advisers before making investment decisions. The formation of the joint venture, while promising, involves business risks and uncertainties that could impact future performance and share price.

View ZHONG JI LS Historical chart here